Fulcrum Asset Management LLP Acquires 18,291 Shares of Abbott Laboratories $ABT

Fulcrum Asset Management LLP lifted its holdings in shares of Abbott Laboratories (NYSE:ABT) by 28.8% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 81,700 shares of the healthcare product maker’s stock after acquiring an additional 18,291 shares during the period. Fulcrum Asset Management LLP’s holdings in Abbott Laboratories were worth $8,248,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of the business. Manning & Napier Advisors LLC acquired a new stake in Abbott Laboratories during the 2nd quarter worth $31,000. Foresight Capital Management Advisors Inc. purchased a new position in shares of Abbott Laboratories during the third quarter worth about $31,000. Balance Wealth Partners LLC purchased a new position in shares of Abbott Laboratories during the third quarter worth about $34,000. Summit Securities Group LLC grew its holdings in shares of Abbott Laboratories by 41.3% during the second quarter. Summit Securities Group LLC now owns 404 shares of the healthcare product maker’s stock worth $37,000 after buying an additional 118 shares during the last quarter. Finally, Addison Advisors LLC acquired a new position in Abbott Laboratories in the 2nd quarter valued at about $40,000. 75.18% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In related news, EVP Mary Moreland sold 3,500 shares of the firm’s stock in a transaction dated Thursday, November 5th. The shares were sold at an average price of $116.00, for a total value of $406,000.00. Following the completion of the sale, the executive vice president owned 100,791 shares in the company, valued at $11,691,756. This trade represents a 3.36% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.46% of the stock is owned by corporate insiders.

Abbott Laboratories Stock Up 0.1%

ABT opened at $110.02 on Monday. The business has a 50 day simple moving average of $104.04 and a 200-day simple moving average of $101.78. Abbott Laboratories has a 12 month low of $81.97 and a 12 month high of $132.02. The stock has a market capitalization of $190.38 billion, a P/E ratio of 41.05, a P/E/G ratio of 1.93 and a beta of 0.54. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.45 and a quick ratio of 1.00.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings data on Wednesday, October 21st. The healthcare product maker reported $1.42 earnings per share (EPS) for the quarter, hitting the consensus estimate of $1.42. Abbott Laboratories had a return on equity of 18.04% and a net margin of 9.75%. The firm had revenue of $13.01 billion during the quarter, compared to analysts’ expectations of $12.99 billion. During the same quarter in the prior year, the business posted $1.30 earnings per share. Abbott Laboratories’s revenue was up 14.5% compared to the same quarter last year. On average, equities analysts anticipate that Abbott Laboratories will post 5.52 earnings per share for the current fiscal year.

Abbott Laboratories Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, November 16th. Stockholders of record on Thursday, October 15th will be issued a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.3%. The ex-dividend date is Thursday, October 15th. Abbott Laboratories’s dividend payout ratio (DPR) is currently 94.03%.

Analyst Ratings Changes

Several analysts have commented on ABT shares. Wall Street Zen raised Abbott Laboratories from a “hold” rating to a “buy” rating in a research note on Saturday, October 24th. Weiss Ratings upgraded Abbott Laboratories from a “hold (c-)” rating to a “hold (c)” rating in a research note on Friday, September 18th. Robert W. Baird lifted their target price on Abbott Laboratories from $121.00 to $123.00 and gave the company an “outperform” rating in a research note on Thursday, October 22nd. Citigroup decreased their price target on Abbott Laboratories from $125.00 to $122.00 and set a “buy” rating for the company in a report on Thursday, October 22nd. Finally, Royal Bank Of Canada lowered their price objective on shares of Abbott Laboratories from $130.00 to $125.00 and set an “outperform” rating on the stock in a research report on Thursday, October 22nd. Two investment analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and five have given a Hold rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $118.32.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company that develops, manufactures and markets medical devices, diagnostic tests, nutritional products and branded generic medicines. Its products serve patients and healthcare professionals in hospitals, clinics and other care settings.

Abbott’s offerings include the FreeStyle Libre continuous glucose monitoring system, cardiovascular and other medical devices, laboratory and rapid diagnostic tests, and nutrition brands such as Ensure and Similac.